Latest News for: dmd

Edit

The Anti-VC Blockchain: A Deep Dive into DMD Diamond’s “Infinite Life” Economy

BitRSS 24 Dec 2025
... and massive marketing budgets, DMD Diamond (est.
Edit

DMD urges precautions as fog, cold intensify across state

The Times of India 17 Dec 2025
+Text SizeSmallMediumLarge. .
Edit

Inclusive disaster preparedness key to effective response: DMD

The Times of India 17 Dec 2025
+Text SizeSmallMediumLarge. .
Edit

Wicker Applauds HHS DMD Announcement (Roger F Wicker)

Public Technologies 17 Dec 2025
"Nearly 25 years ago, a Mississippian visited my office and told me his son had been diagnosed with DMD ... It has been among my greatest joys in Congress to help combat DMD and other muscular dystrophies ... I will continue to bring awareness to DMD.
Edit

Rein in presidential pardons with balance and accountability

The Hill 10 Dec 2025
....
Edit

Positive Topline Results from DELIVER Trial of Z Rostudirsen in DMD (Dyne Therapeutics Inc)

Public Technologies 08 Dec 2025
) Positive Topline Results from Phase 1/2 DELIVER Trial of Zeleciment Rostudirsen (DYNE-251) in DMD to Support Potential ... Ravi, living with DMD ... Positive results from Registrational Expansion Cohort of DELIVER trial of z-rostudirsen in exon 51 DMD.
Edit

Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) (Form 8-K) (Dyne Therapeutics Inc)

Public Technologies 08 Dec 2025
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) ... In DMD, loss of pulmonary function is a leading cause of mortality4 ... About Duchenne Muscular Dystrophy (DMD).
Edit

Roche supports Sidra Medicine’s global DMD exchange, spotlighting Qatar as a gene therapy hub

The Peninsula 27 Nov 2025
Roche Pharmaceuticals, through its local representative Ebn Sina Medical, a fully owned subsidiary of Aamal Company Q.P.S.C will co-organise the Duchenne Muscular Dystrophy (DMD) Peer-to-Peer Exchange 2025 at Sidra Medicine.
Edit

Gov. Hochul can lead the nation in gene therapy access for our children

Nashville Pride 25 Nov 2025
Elevidys is the only FDA-approved gene therapy for Duchenne’s Muscular Dystrophy (DMD), an incurable rare genetic disease that causes irreversible muscle loss at a fatal rate.
Edit

Real anchor of cedi lies in productivity of industries and people – Fidelity DMD Kwabena Boateng

B & FT Online 05 Nov 2025
Fidelity Bank’s Deputy Managing Director for Wholesale Banking, Mr ... Speaking at the 14th Ghana Economic Forum held at the Kempinski Gold Coast Hotel, on the theme “Currency Value Addition – A Reset for Sustainable Economic Growth,” Mr ... Boateng said ... Mr.
Edit

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable ...

Nasdaq Globe Newswire 04 Nov 2025
... (vamorolone) in patients with Duchenne muscular dystrophy (DMD).
Edit

Five-year data of AGAMREE� (vamorolone) in patients with DMD show improved safety profile with comparable ...

Nasdaq Globe Newswire 04 Nov 2025
Ad hoc announcement pursuant to Art. 53 LR ... .
Edit

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids

Pharmiweb 04 Nov 2025
Having shared the data with members of our scientific steering committee, all KOLs in the DMD field, we are very encouraged by their response ... AGAMREE for the treatment of DMD is approved in the U.S.
Edit

Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids (Santhera Pharmaceuticals Holding AG)

Public Technologies 04 Nov 2025
53 LR Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids ... AGAMREE for the treatment of DMD is approved in the U.S.
Edit

Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial

The Call 04 Nov 2025
The biopharmaceutical company revealed that its Phase 3 ESSENCE study, evaluating the efficacy of its Duchenne muscular dystrophy (DMD) therapies Amondys 45 (casimersen) and Vyondys 53 (golodirsen), failed to meet its primary endpoint.

Article Search

tools
×
×
×
×